Alnylam Pharmaceuticals
ALNY
#378
Rank
HK$471.15 B
Marketcap
HK$3,566
Share price
-1.55%
Change (1 day)
82.00%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of September 2025 : HK$10.18 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is HK$10.18 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2025)

Total debt by year

Year Total debt Change
2024-12-31HK$10.06 B-1.31%
2023-12-31HK$10.19 B-1.17%
2022-12-31HK$10.31 B32.61%
2021-12-31HK$7.77 B92.53%
2020-12-31HK$4.04 B70.75%
2019-12-31HK$2.36 B907.21%
2018-12-31HK$0.23 B0.23%
2017-12-31HK$0.23 B-79.85%
2016-12-31HK$1.16 B
2007-12-31HK$52.69 M-25.84%
2006-12-31HK$71.05 M23.93%
2005-12-31HK$57.33 M2.46%
2004-12-31HK$55.96 M288.36%
2003-12-31HK$14.4 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Arrowhead Pharmaceuticals
ARWR
HK$2.74 B-73.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
HK$21.06 B 106.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
HK$9.73 B-4.45%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
HK$3.07 B-69.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
HK$10.9 M-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
HK$249.27 B 2,347.32%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
HK$198.75 B 1,851.26%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
HK$132.90 B 1,204.83%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel